<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556203</url>
  </required_header>
  <id_info>
    <org_study_id>17938</org_study_id>
    <secondary_id>2015-001975-30</secondary_id>
    <nct_id>NCT02556203</nct_id>
  </id_info>
  <brief_title>Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes</brief_title>
  <acronym>GALILEO</acronym>
  <official_title>Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR,
      compared to an antiplatelet-based strategy, is superior in reducing death or first
      thromboembolic events (DTE).

      To assess the primary bleeding events (PBE) of the rivaroxaban-based strategy compared to an
      antiplatelet-based strategy, following TAVR.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator
  </why_stopped>
  <start_date type="Actual">December 16, 2015</start_date>
  <completion_date type="Actual">November 27, 2018</completion_date>
  <primary_completion_date type="Actual">November 27, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Death or First Thromboembolic Event (DTE)</measure>
    <time_frame>Through study completion, on average 14 months</time_frame>
    <description>Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Death or First Thromboembolic Event (DTE)</measure>
    <time_frame>Through study completion, on average 16 months</time_frame>
    <description>Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Primary Bleeding Event (PBE)</measure>
    <time_frame>Through study completion, on average 16 months</time_frame>
    <description>PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Net-clinical Benefit</measure>
    <time_frame>Through study completion, on average 16 months</time_frame>
    <description>The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Death or Thromboembolic Event</measure>
    <time_frame>Through study completion, on average 16 months</time_frame>
    <description>Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds</measure>
    <time_frame>Through study completion, on average 16 months</time_frame>
    <description>Composite of TIMI major and minor bleedings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds</measure>
    <time_frame>Through study completion, on average 16 months</time_frame>
    <description>ISTH major bleeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds</measure>
    <time_frame>Through study completion, on average 16 months</time_frame>
    <description>Composite of BARC 2,3 or 5 bleedings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1653</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiplatelet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>10mg OD (once-daily)</description>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic Acid (ASA)</intervention_name>
    <description>75-100mg OD</description>
    <arm_group_label>Antiplatelet</arm_group_label>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75mg OD</description>
    <arm_group_label>Antiplatelet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>In case of NOAF, 20/15 mg OD (once-daily)</description>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist (VKA)</intervention_name>
    <description>In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines</description>
    <arm_group_label>Antiplatelet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful TAVR (Transcatheter Aortic Valve Replacement) of an aortic valve stenosis
             (either native or valve-in-valve)

               -  By iliofemoral or subclavian access

               -  With any approved/marketed device

        Exclusion Criteria:

          -  Atrial fibrillation (AF), current or previous, with an ongoing indication for oral
             anticoagulant treatment

          -  Any other indication for continued treatment with any oral anticoagulant (OAC)

          -  Known bleeding diathesis (such as but not limited to active internal bleeding,
             clinically significant bleeding, platelet count ≤ 50,000/mm3 at screening, hemoglobin
             level &lt; 8.5 g/dL, active peptic ulcer or known gastrointestinal (GI) bleeding, history
             of intracranial hemorrhage or subdural hematoma)

          -  Any ongoing absolute indication for dual antiplatelet therapy (DAPT) at time of
             screening that is unrelated to the TAVR procedure

          -  Clinically overt stroke within the last 3 months

          -  Planned coronary or vascular intervention or major surgery

          -  Severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2) or on dialysis, or post-TAVR
             unresolved acute kidney injury with renal dysfunction stage 2 or higher

          -  Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic
             disease associated with coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-0750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030-3876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711-3752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wels</city>
        <state>Oberösterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6A 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Konstanz</city>
        <state>Baden-Württemberg</state>
        <zip>78464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahr</city>
        <state>Baden-Württemberg</state>
        <zip>77033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Neustadt</city>
        <state>Bayern</state>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotenburg A.d. Fulda</city>
        <state>Hessen</state>
        <zip>36199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Berka</city>
        <state>Thüringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <state>North Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <zip>OX9 3DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 5, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <results_first_submitted>November 22, 2019</results_first_submitted>
  <results_first_submitted_qc>December 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVR</keyword>
  <keyword>TAVI</keyword>
  <keyword>Transfemoral aortic valve implantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02556203/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02556203/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at 136 centers world-wide between 16 Dec 2015 (first patient’s first visit) and 27 Nov 2018 (last patient’s last visit).</recruitment_details>
      <pre_assignment_details>A total of 1674 subjects were screened, of which 1644 were randomly assigned to either of the two treatment arms and 1608 subjects started treatment with study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
          <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
        </group>
        <group group_id="P2">
          <title>Antiplatelet</title>
          <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="826"/>
                <participants group_id="P2" count="818"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="801"/>
                <participants group_id="P2" count="807"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="799"/>
                <participants group_id="P2" count="792"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
          <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
        </group>
        <group group_id="B2">
          <title>Antiplatelet</title>
          <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="826"/>
            <count group_id="B2" value="818"/>
            <count group_id="B3" value="1644"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.38" spread="7.12"/>
                    <measurement group_id="B2" value="80.77" spread="5.99"/>
                    <measurement group_id="B3" value="80.57" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="400"/>
                    <measurement group_id="B2" value="413"/>
                    <measurement group_id="B3" value="813"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="405"/>
                    <measurement group_id="B3" value="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="677"/>
                    <measurement group_id="B2" value="694"/>
                    <measurement group_id="B3" value="1371"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="692"/>
                    <measurement group_id="B2" value="693"/>
                    <measurement group_id="B3" value="1385"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Death or First Thromboembolic Event (DTE)</title>
        <description>Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism.</description>
        <time_frame>Through study completion, on average 14 months</time_frame>
        <population>Safety analysis set (SAF): Included all randomized subjects who had been exposed to study drug at least once (1608 subjects overall).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or First Thromboembolic Event (DTE)</title>
          <description>Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism.</description>
          <population>Safety analysis set (SAF): Included all randomized subjects who had been exposed to study drug at least once (1608 subjects overall).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: HR(t)&gt;=1.20 for all time points t&gt;=0, (i.e. “the hazard for the primary efficacy endpoint in the rivaroxaban-based treatment group is more than 20% larger than that in the antiplatelet-based control group”)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>1-sided Confidence interval</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.2089302</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.7040824</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Death or First Thromboembolic Event (DTE)</title>
        <description>Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism.</description>
        <time_frame>Through study completion, on average 16 months</time_frame>
        <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall)</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or First Thromboembolic Event (DTE)</title>
          <description>Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism.</description>
          <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>2-sided Log Rank test</non_inferiority_desc>
            <p_value>= 0.04223</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Primary Bleeding Event (PBE)</title>
        <description>PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding.</description>
        <time_frame>Through study completion, on average 16 months</time_frame>
        <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Primary Bleeding Event (PBE)</title>
          <description>PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding.</description>
          <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive. 2-sided Log Rank test.</non_inferiority_desc>
            <p_value>= 0.07745</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
            <estimate_desc>Estimates for HRs are based on Cox proportional hazards model. HRs &gt;1 indicate a higher hazard rate in the rivaroxaban arm compared with the antiplatelet arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Net-clinical Benefit</title>
        <description>The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety).</description>
        <time_frame>Through study completion, on average 16 months</time_frame>
        <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Net-clinical Benefit</title>
          <description>The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety).</description>
          <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>2-sided Log Rank test</non_inferiority_desc>
            <p_value>= 0.01156</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
            <estimate_desc>Estimates for HRs are based on Cox proportional hazards model. HRs &gt;1 indicate a higher hazard rate in the rivaroxaban arm compared with the antiplatelet arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Death or Thromboembolic Event</title>
        <description>Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication).</description>
        <time_frame>Through study completion, on average 16 months</time_frame>
        <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Death or Thromboembolic Event</title>
          <description>Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication).</description>
          <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>2-sided Log Rank test</non_inferiority_desc>
            <p_value>= 0.21595</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
            <estimate_desc>Estimates for HRs are based on Cox proportional hazards model. HRs &gt;1 indicate a higher hazard rate in the rivaroxaban arm compared with the antiplatelet arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds</title>
        <description>Composite of TIMI major and minor bleedings</description>
        <time_frame>Through study completion, on average 16 months</time_frame>
        <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds</title>
          <description>Composite of TIMI major and minor bleedings</description>
          <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive. 2-sided Log Rank test.</non_inferiority_desc>
            <p_value>= 0.02216</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
            <estimate_desc>Estimates for HRs are based on Cox proportional hazards model. HRs &gt;1 indicate a higher hazard rate in the rivaroxaban arm compared with the antiplatelet arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds</title>
        <description>ISTH major bleeds</description>
        <time_frame>Through study completion, on average 16 months</time_frame>
        <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds</title>
          <description>ISTH major bleeds</description>
          <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive. 2-sided Log Rank test.</non_inferiority_desc>
            <p_value>= 0.02702</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
            <estimate_desc>Estimates for HRs are based on Cox proportional hazards model. HRs &gt;1 indicate a higher hazard rate in the rivaroxaban arm compared with the antiplatelet arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds</title>
        <description>Composite of BARC 2,3 or 5 bleedings</description>
        <time_frame>Through study completion, on average 16 months</time_frame>
        <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (Acetylsalicylic Acid) (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
          </group>
          <group group_id="O2">
            <title>Antiplatelet</title>
            <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds</title>
          <description>Composite of BARC 2,3 or 5 bleedings</description>
          <population>Full analysis set (FAS): Included all randomized subjects and results presented according to randomized treatment arm (1644 subjects overall).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive. 2-sided Log Rank test.</non_inferiority_desc>
            <p_value>= 0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
            <estimate_desc>Estimates for HRs are based on Cox proportional hazards model. HRs &gt;1 indicate a higher hazard rate in the rivaroxaban arm compared with the antiplatelet arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, on average 14 months. Timeframe for All-Cause Mortality: After study medication start until last contact date.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rivaroxaban Arm</title>
          <description>Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.</description>
        </group>
        <group group_id="E2">
          <title>Antiplatelet Arm</title>
          <description>Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA (Vitamin K antagonist) to target INR (international normalized ratio) 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="801"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="296" subjects_at_risk="801"/>
                <counts group_id="E2" subjects_affected="282" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="801"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="801"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="801"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Coronary ostial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Neuroacanthocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Primary adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Macular detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Coeliac artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pacemaker generated arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Haemophagocytic lymphohistiocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="801"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="801"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac valve abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Streptococcal endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Medical device site joint infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pancreatic injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Coronary bypass stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Arterial bypass stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Post procedural hypoparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Product administration error</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Inflammatory marker increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Transvalvular pressure gradient increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ear neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Axonal neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="801"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ballismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Undersensing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="801"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cochlea implant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Incisional hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin cyst excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peripheral artery angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dental operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ear operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Eyelid operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker adjustment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Transcatheter arterial chemoembolisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.2</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="359" subjects_at_risk="801"/>
                <counts group_id="E2" subjects_affected="302" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="44" subjects_affected="43" subjects_at_risk="801"/>
                <counts group_id="E2" events="45" subjects_affected="44" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="801"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="801"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="801"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="801"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="801"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="801"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="801"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="801"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="801"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="801"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="801"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QRS complex prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>International normalised ratio abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Transvalvular pressure gradient increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="801"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="801"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="801"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="801"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="801"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="801"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="801"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="801"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="801"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="807"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer</organization>
      <phone>(+)1-888-84 22937</phone>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

